What is STANDARD BIOTOOLS INC's earnings per share (EPS)?

STANDARD BIOTOOLS INC (LAB) reported diluted earnings per share of -$0.20 for fiscal year 2025. This represents a 61.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

STANDARD BIOTOOLS INC Financials

LAB

Trailing 12 months to June 30, 2026

Revenue $84.6M +30.2% YoY

Net Income $84.9M +170.5% YoY

EPS (Diluted) $0.22 +171.0% YoY

Free Cash Flow -$82.6M +21.7% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

STANDARD BIOTOOLS INC (LAB) reported $84.6M in revenue over the twelve months to Jun 30, 2026, up 30.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LAB FY2025 2026-08-26

Standard BioTools remains a cash-consuming operating model with improving gross economics but losses still absorbing the funding base.

Revenue declined to $85.3M in FY2025 while gross margin reached 49.9%, suggesting unit-level economics improved even as the business stayed too expense-heavy to profit. Net loss narrowed to -$74.9M and operating cash flow improved to -$74.3M, so accounting losses and cash use broadly aligned rather than reflecting a large conversion gap.

Equity moved from -$148.1M in FY2023 to $471.7M in FY2024, materially changing the balance-sheet posture. That reset coincided with shares outstanding rising to 377.5M, indicating the stronger capital base was not created by operating profits.

The FY2025 current ratio was 4.2x, indicating substantial short-term asset coverage. Reported liquidity equaled 34.4 months of the latest annual operating outflow while operating cash flow remained -$74.3M, making internal cash generation the central operating constraint.

Financial Health Signals

Financial Health Score 43/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of STANDARD BIOTOOLS INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-1.81

STANDARD BIOTOOLS INC scores -1.81, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($252.0M) relative to total liabilities ($143.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

STANDARD BIOTOOLS INC passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

STANDARD BIOTOOLS INC reported a net loss of $74.9M while operations used $74.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

STANDARD BIOTOOLS INC reported an operating loss of $110.2M against $26K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$85.3M

YoY-6.2%

5Y CAGR-9.2%

10Y CAGR-2.9%

STANDARD BIOTOOLS INC generated $85.3M in revenue in fiscal year 2025. This represents a decrease of 6.2% from the prior year.

EBITDA

-$101.0M

YoY+12.3%

STANDARD BIOTOOLS INC's EBITDA was -$101.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.3% from the prior year.

Net Income

-$74.9M

YoY+46.1%

STANDARD BIOTOOLS INC reported -$74.9M in net income in fiscal year 2025. This represents an increase of 46.1% from the prior year.

EPS (Diluted)

-$0.20

YoY+61.5%

STANDARD BIOTOOLS INC earned -$0.20 per diluted share (EPS) in fiscal year 2025. This represents an increase of 61.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$82.6M

YoY+45.6%

STANDARD BIOTOOLS INC recorded an outflow of $82.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 45.6% from the prior year.

Cash & Debt

$120.9M

YoY-27.5%

5Y CAGR+12.0%

10Y CAGR+15.3%

STANDARD BIOTOOLS INC held $120.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

390M

YoY+2.9%

STANDARD BIOTOOLS INC had 390M shares outstanding in fiscal year 2025. This represents an increase of 2.9% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

49.9%

YoY+0.5pp

STANDARD BIOTOOLS INC's gross margin was 49.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the prior year.

Net Margin

-87.8%

5Y CAGR-49.4pp

10Y CAGR-41.3pp

STANDARD BIOTOOLS INC's net profit margin was -87.8% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

-17.6%

YoY+11.8pp

STANDARD BIOTOOLS INC's ROE was -17.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 11.8 percentage points from the prior year.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$26.0M

YoY-9.9%

5Y CAGR-6.5%

10Y CAGR-4.0%

STANDARD BIOTOOLS INC invested $26.0M in research and development in fiscal year 2025. This represents a decrease of 9.9% from the prior year.

Share Buybacks

YoY-100.0%

STANDARD BIOTOOLS INC repurchased no shares in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

Capital Expenditures

$8.3M

YoY-0.6%

5Y CAGR-8.2%

10Y CAGR+7.6%

STANDARD BIOTOOLS INC invested $8.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 0.6% from the prior year.

LAB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

LAB quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$84.6M	$85.3M-6.2%	$91.0M-14.4%	$106.3M+8.6%	$97.9M-25.0%	$130.6M-5.5%	$138.1M+17.8%	$117.2M+3.8%	$113.0M+10.8%	$101.9M-2.4%	$104.4M-8.9%	$114.7M-1.5%	$116.5M+63.6%	$71.2M+36.0%	$52.3M+22.1%	$42.9M
Cost of Revenue	$41.9M	$42.8M-7.2%	$46.1M-17.5%	$55.9M-8.2%	$60.9M	N/A	N/A	$53.0M+3.2%	$51.3M+2.7%	$50.0M+8.6%	$46.0M+15236.3%	$300K0.0%	$300K0.0%	$300K0.0%	$300K+200.0%	$100K
Gross Profit	$42.7M	$42.5M-5.2%	$44.9M-11.0%	$50.5M+36.2%	$37.1M	N/A	N/A	$64.3M+4.3%	$61.6M+18.6%	$52.0M-11.0%	$58.4M-48.9%	$114.4M-1.5%	$116.2M+63.9%	$70.9M+36.2%	$52.0M+21.7%	$42.8M
R&D Expenses	$18.4M	$26.0M-9.9%	$28.8M+11.1%	$25.9M-30.6%	$37.4M-1.5%	$37.9M+4.1%	$36.5M+15.2%	$31.6M+5.4%	$30.0M-2.6%	$30.8M-19.8%	$38.4M-2.2%	$39.3M-9.6%	$43.4M+117.6%	$20.0M+20.2%	$16.6M+19.1%	$13.9M
SG&A Expenses	$86.9M	$109.9M+6.6%	$103.1M+17.7%	$87.5M-14.4%	$102.3M+3.4%	$98.9M+1.0%	$97.9M+15.9%	$84.5M+5.9%	$79.8M+0.3%	$79.5M-14.7%	$93.2M+12.4%	$83.0M+16.3%	$71.3M+47.3%	$48.4M+25.8%	$38.5M+22.9%	$31.3M
Operating Income	-$95.5M	-$110.2M+13.5%	-$127.5M-66.4%	-$76.6M+34.1%	-$116.2M-72.3%	-$67.5M-32.2%	-$51.0M+1.5%	-$51.8M-7.6%	-$48.2M+17.5%	-$58.4M+20.3%	-$73.2M-45.9%	-$50.2M+3.2%	-$51.8M-177.9%	-$18.7M-3.2%	-$18.1M+2.7%	-$18.6M
Interest Expense	N/A	$26K-99.2%	$3.3M-27.4%	$4.6M+5.4%	$4.3M+13.3%	$3.8M+7.0%	$3.6M-16.5%	$4.3M-69.2%	$13.9M+138.5%	$5.8M+0.1%	$5.8M+0.2%	$5.8M+8.7%	$5.3M+38071.4%	$14K-97.8%	$628K-79.7%	$3.1M
Income Tax	-$37.0M	-$37.9M-7088.2%	$542K+19.9%	$452K+116.0%	-$2.8M+36.0%	-$4.4M-309.2%	-$1.1M+43.6%	-$1.9M+20.4%	-$2.4M+26.3%	-$3.3M+22.1%	-$4.2M-184.2%	-$1.5M+69.7%	-$4.9M-3658.4%	$137K+0.7%	$136K-18.1%	$166K
Net Income	$84.9M	-$74.9M+46.1%	-$138.9M-86.0%	-$74.7M+60.7%	-$190.1M-220.9%	-$59.2M-11.7%	-$53.0M+18.2%	-$64.8M-9.8%	-$59.0M+2.5%	-$60.5M+20.3%	-$76.0M-42.5%	-$53.3M-0.9%	-$52.8M-219.7%	-$16.5M+13.1%	-$19.0M+15.3%	-$22.5M
EPS (Diluted)	$0.22	-$0.20+61.5%	-$0.52	-$0.94	-$2.43-211.5%	-$0.78-5.4%	-$0.74+23.7%	-$0.97	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$20.1M-4.9%	$21.1M-11.1%	$23.8M+21.7%	$19.6M-10.2%	$21.8M+7.6%	$20.2M+2172.1%	$890K-96.0%	$22.1M
Cost of Revenue	$9.6M-2.7%	$9.8M-20.7%	$12.4M+23.3%	$10.1M-9.6%	$11.1M+21.4%	$9.2M+240.4%	$2.7M-72.9%	$10.0M
Gross Profit	$10.5M-6.8%	$11.3M-0.7%	$11.4M+20.0%	$9.5M-10.8%	$10.6M-3.8%	$11.0M+712.1%	-$1.8M-114.9%	$12.1M
R&D Expenses	$2.0M-6.7%	$2.1M-73.4%	$8.0M+25.4%	$6.4M+2.2%	$6.2M+14.4%	$5.4M+308.4%	-$1.3M-80.8%	$6.9M
SG&A Expenses	$16.4M-11.9%	$18.6M-26.6%	$25.3M-4.7%	$26.6M-5.4%	$28.1M-5.8%	$29.8M+339.3%	$6.8M-72.3%	$24.5M
Operating Income	-$25.4M-103.2%	-$12.5M+49.3%	-$24.6M+25.2%	-$32.9M-28.2%	-$25.7M+4.7%	-$27.0M-160.8%	-$10.3M+61.3%	-$26.7M
Interest Expense	N/A	N/A	$5K-50.0%	$10K+11.1%	$9K+350.0%	$2K-99.7%	$572K-32.9%	$853K
Income Tax	$90K+718.2%	$11K+100.0%	-$35.9M-2854.9%	-$1.2M-99.7%	-$609K-411.8%	-$119K-146.3%	$257K+117.8%	$118K
Net Income	-$26.8M-121.1%	$127.1M+559.0%	$19.3M+155.6%	-$34.7M-3.7%	-$33.5M-28.5%	-$26.0M+23.6%	-$34.1M-26.5%	-$26.9M
EPS (Diluted)	-$0.07-121.2%	$0.33+560.0%	$0.05+155.6%	-$0.090.0%	-$0.09-28.6%	-$0.07+12.5%	-$0.08-14.3%	-$0.07

LAB Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

LAB quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$567.8M-7.3%	$612.3M+89.5%	$323.1M-17.2%	$390.3M+41.8%	$275.2M-15.3%	$324.8M+22.6%	$264.8M-12.8%	$303.6M+5.7%	$287.4M-6.2%	$306.4M-17.2%	$370.1M-9.2%	$407.6M+248.6%	$116.9M+2.8%	$113.7M+43.4%	$79.3M
Current Assets	$454.3M+20.9%	$375.9M+137.6%	$158.2M-24.2%	$208.8M+189.8%	$72.1M-38.8%	$117.7M+22.4%	$96.1M-24.4%	$127.1M+34.1%	$94.8M-1.9%	$96.7M-32.9%	$144.1M-7.6%	$155.9M+49.1%	$104.6M+3.3%	$101.2M+44.5%	$70.0M
Cash & Equivalents	$120.9M-27.5%	$166.7M+222.5%	$51.7M-36.4%	$81.3M+185.8%	$28.5M-58.5%	$68.5M+216.3%	$21.7M-77.3%	$95.4M+64.3%	$58.1M+65.7%	$35.0M+20.4%	$29.1M-13.6%	$33.7M-4.4%	$35.3M-39.9%	$58.6M+332.7%	$13.6M
Inventory	$20.0M-3.7%	$20.7M+1.0%	$20.5M-4.4%	$21.5M+3.1%	$20.8M+5.8%	$19.7M+41.8%	$13.9M+6.8%	$13.0M-13.8%	$15.1M-25.0%	$20.1M+12.2%	$17.9M+12.1%	$16.0M+96.3%	$8.1M+13.7%	$7.2M+20.1%	$6.0M
Accounts Receivable	$13.4M-8.9%	$14.7M-25.0%	$19.7M+13.8%	$17.3M-5.7%	$18.3M-27.9%	$25.4M+33.9%	$19.0M+14.0%	$16.7M+10.6%	$15.0M+3.0%	$14.6M-42.6%	$25.5M+13.7%	$22.4M+112.1%	$10.6M-18.2%	$12.9M+39.4%	$9.3M
Goodwill	N/A	$111.3M+4.7%	$106.3M+0.1%	$106.3M-0.1%	$106.4M-0.2%	$106.6M+2.4%	$104.1M0.0%	$104.1M0.0%	$104.1M0.0%	$104.1M0.0%	$104.1M0.0%	$104.1M	$0	N/A	N/A
Total Liabilities	$143.5M+2.0%	$140.6M-70.2%	$471.1M-0.1%	$471.8M+161.2%	$180.6M-2.7%	$185.7M+67.0%	$111.2M-52.0%	$231.5M-9.7%	$256.4M+1.3%	$253.2M-0.8%	$255.1M-0.8%	$257.1M+1154.3%	$20.5M+56.8%	$13.1M-41.7%	$22.4M
Current Liabilities	$108.3M+64.4%	$65.9M-39.7%	$109.3M+151.7%	$43.4M-12.4%	$49.6M-8.6%	$54.2M+65.3%	$32.8M-12.7%	$37.6M+12.3%	$33.5M+13.5%	$29.5M-1.9%	$30.1M+2.4%	$29.4M+63.7%	$18.0M+54.8%	$11.6M-42.5%	$20.2M
Long-Term Debt	N/A	$299K-99.5%	$63.5M-2.1%	$64.9M	N/A	N/A	N/A	N/A	$195.2M	N/A	N/A	N/A	N/A	$0-100.0%	$1.2M
Total Equity	$424.3M-10.1%	$471.7M+418.6%	-$148.1M-81.7%	-$81.5M-186.1%	$94.6M-32.0%	$139.1M-9.5%	$153.6M+113.0%	$72.1M+133.1%	$30.9M-41.9%	$53.2M-53.7%	$114.9M-23.6%	$150.4M+56.0%	$96.4M-4.2%	$100.7M+76.9%	$56.9M
Retained Earnings	-$1.3B-6.3%	-$1.2B-18.5%	-$1.0B-8.1%	-$926.1M-25.8%	-$736.0M-8.8%	-$676.8M-8.5%	-$623.6M-11.6%	-$558.9M-11.7%	-$500.2M-13.8%	-$439.5M-20.9%	-$363.5M-17.2%	-$310.2M-20.5%	-$257.3M-6.9%	-$240.8M-8.6%	-$221.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$627.2M-1.9%	$639.1M+12.6%	$567.8M+5.2%	$539.6M-3.1%	$557.0M-3.9%	$579.6M-5.3%	$612.3M-10.2%	$681.5M
Current Assets	$516.9M-0.9%	$521.5M+14.8%	$454.3M-3.8%	$472.4M-6.6%	$506.0M+47.1%	$344.0M-8.5%	$375.9M-17.1%	$453.6M
Cash & Equivalents	$270.0M+1.6%	$265.8M+119.9%	$120.9M-6.6%	$129.4M-18.4%	$158.6M+5.1%	$150.9M-9.5%	$166.7M-20.8%	$210.6M
Inventory	$17.1M-8.0%	$18.6M-6.9%	$20.0M-21.4%	$25.4M+5.2%	$24.2M-42.6%	$42.1M+103.1%	$20.7M-51.4%	$42.6M
Accounts Receivable	$15.7M-5.3%	$16.6M+23.9%	$13.4M-0.8%	$13.5M-7.4%	$14.6M-58.8%	$35.5M+140.7%	$14.7M-58.3%	$35.3M
Goodwill	N/A	N/A	N/A	N/A	N/A	$111.7M+0.4%	$111.3M+4.7%	$106.3M
Total Liabilities	$87.2M+11.9%	$78.0M-45.6%	$143.5M+2.5%	$140.0M+5.7%	$132.4M+5.9%	$125.0M-11.1%	$140.6M-26.8%	$192.2M
Current Liabilities	$56.8M+34.6%	$42.2M-61.0%	$108.3M+0.3%	$108.0M+10.1%	$98.0M+74.3%	$56.2M-14.7%	$65.9M-45.4%	$120.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$299K-99.5%	$55.2M
Total Equity	$540.0M-3.8%	$561.1M+32.2%	$424.3M+6.2%	$399.7M-5.9%	$424.5M-6.6%	$454.6M-3.6%	$471.7M-3.6%	$489.3M
Retained Earnings	-$1.2B-2.4%	-$1.1B+10.1%	-$1.3B+1.5%	-$1.3B-2.8%	-$1.2B-2.8%	-$1.2B-2.2%	-$1.2B-3.0%	-$1.2B

LAB Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

LAB quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$80.3M	-$74.3M+48.2%	-$143.5M-231.4%	-$43.3M+51.6%	-$89.4M-102.8%	-$44.1M-185.8%	-$15.4M+56.2%	-$35.2M-39.7%	-$25.2M-4.6%	-$24.1M+38.4%	-$39.1M-12.7%	-$34.7M-53.5%	-$22.6M-1321.9%	-$1.6M+90.9%	-$17.5M+0.4%	-$17.5M
Capital Expenditures	$2.3M	$8.3M-0.6%	$8.4M+195.1%	$2.8M-26.0%	$3.8M-71.2%	$13.3M+4.3%	$12.7M+402.4%	$2.5M+580.4%	$372K-76.2%	$1.6M-69.1%	$5.1M+27.2%	$4.0M-46.2%	$7.4M+114.8%	$3.4M+44.5%	$2.4M+42.2%	$1.7M
Free Cash Flow	-$82.6M	-$82.6M+45.6%	-$151.8M-229.2%	-$46.1M+50.5%	-$93.2M-62.6%	-$57.3M-103.8%	-$28.1M+25.5%	-$37.7M-47.6%	-$25.6M+0.4%	-$25.7M+41.9%	-$44.2M-14.2%	-$38.7M-28.9%	-$30.0M-496.1%	-$5.0M+74.6%	-$19.9M-3.4%	-$19.2M
Investing Cash Flow	$190.8M	$27.4M-92.5%	$363.2M+1694.6%	$20.2M+123.0%	-$88.1M-637.7%	-$11.9M-129.9%	$40.0M+201.7%	-$39.3M-932.8%	$4.7M-73.3%	$17.7M-60.8%	$45.1M+75.2%	$25.7M+114.4%	-$178.4M-547.1%	-$27.6M-296.9%	$14.0M+131.0%	-$45.1M
Financing Cash Flow	$330K	$570K+100.6%	-$102.6M-1407.1%	-$6.8M-103.0%	$230.8M+1345.9%	$16.0M-23.5%	$20.9M+647.6%	$2.8M-95.2%	$57.7M+98.8%	$29.0M+24897.4%	$116K-97.8%	$5.3M-97.3%	$200.3M+3350.3%	$5.8M-88.0%	$48.5M-31.0%	$70.4M
Share Buybacks	N/A	$0-100.0%	$40.5M+647.9%	$5.4M+861.6%	$563K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$10.3M+77.9%	-$46.6M-3815.7%	-$1.2M+94.6%	-$22.2M-7.4%	-$20.7M+31.8%	-$30.3M-115.4%	-$14.1M+49.6%	-$27.9M
Capital Expenditures	$344K-39.6%	$570K+19.7%	$476K-46.3%	$886K-53.0%	$1.9M-62.7%	$5.1M+49.4%	$3.4M+50.0%	$2.3M
Free Cash Flow	-$10.7M+77.4%	-$47.2M-2731.2%	-$1.7M+92.8%	-$23.1M-2.4%	-$22.6M+36.2%	-$35.3M-102.6%	-$17.4M+42.1%	-$30.1M
Investing Cash Flow	$14.4M-92.5%	$191.1M+2476.7%	-$8.0M-20.3%	-$6.7M-124.3%	$27.5M+88.1%	$14.6M-43.2%	$25.7M+183.3%	-$30.9M
Financing Cash Flow	-$138K-245.0%	-$40K-106.5%	$620K+653.6%	-$112K-203.7%	$108K+334.8%	-$46K+99.9%	-$54.5M-2725900.0%	-$2K
Share Buybacks	N/A	N/A	$0	$0	$0	$0	$0	$0

Not reported in any period shown, so not listed: Dividends Paid.

LAB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

LAB quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	49.9%+0.5pp	49.3%+1.9pp	47.4%+9.6pp	37.8%	N/A	N/A	54.8%+0.3pp	54.6%+3.6pp	51.0%-5.0pp	56.0%-43.8pp	99.7%0.0pp	99.7%+0.2pp	99.6%+0.2pp	99.4%-0.3pp	99.8%
Operating Margin	-129.2%	-140.1%	-72.0%	-118.6%	-51.7%-14.7pp	-36.9%+7.3pp	-44.2%-1.6pp	-42.6%+14.6pp	-57.3%+12.8pp	-70.1%-26.4pp	-43.7%+0.8pp	-44.5%-18.3pp	-26.2%+8.3pp	-34.5%+8.8pp	-43.3%
Net Margin	-87.8%	-152.6%	-70.2%	-194.1%	-45.4%-7.0pp	-38.4%+16.9pp	-55.3%-3.0pp	-52.2%+7.1pp	-59.4%+13.4pp	-72.8%-26.3pp	-46.5%-1.1pp	-45.4%-22.1pp	-23.2%+13.1pp	-36.4%+16.1pp	-52.4%
Return on Equity	-17.6%+11.8pp	-29.4%	N/A	N/A	-62.6%-24.5pp	-38.1%+4.1pp	-42.2%+39.6pp	-81.8%+113.9pp	-195.7%-52.9pp	-142.7%-96.3pp	-46.4%-11.3pp	-35.1%-18.0pp	-17.1%+1.8pp	-18.9%+20.6pp	-39.5%
Return on Assets	-13.2%+9.5pp	-22.7%+0.4pp	-23.1%+25.6pp	-48.7%-27.2pp	-21.5%-5.2pp	-16.3%+8.1pp	-24.5%-5.0pp	-19.4%+1.6pp	-21.1%+3.7pp	-24.8%-10.4pp	-14.4%-1.5pp	-13.0%+1.2pp	-14.1%+2.6pp	-16.7%+11.6pp	-28.3%
Current Ratio	4.19-1.5x	5.70+4.3x	1.45-3.4x	4.81+3.4x	1.45-0.7x	2.17-0.8x	2.93-0.5x	3.38+0.5x	2.83-0.4x	3.28-1.5x	4.79-0.5x	5.31-0.5x	5.83-2.9x	8.73+5.3x	3.47
Debt-to-Equity	0.34+0.3x	0.00	N/A	N/A	1.91+0.6x	1.34+0.6x	0.72-2.5x	3.21-3.1x	6.31+1.6x	4.76+2.5x	2.22+0.5x	1.71+1.5x	0.21+0.2x	0.000.0x	0.02
FCF Margin	-96.9%	-166.8%	-43.4%+51.8pp	-95.2%-51.2pp	-43.9%-23.5pp	-20.4%+11.8pp	-32.2%-9.6pp	-22.6%+2.5pp	-25.2%+17.1pp	-42.3%-8.6pp	-33.8%-8.0pp	-25.8%-18.7pp	-7.1%+30.9pp	-38.0%+6.9pp	-44.8%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	52.4%-1.1pp	53.5%+5.7pp	47.8%-0.7pp	48.5%-0.3pp	48.8%-5.8pp	54.6%	-202.8%	54.9%
Operating Margin	-126.3%	-59.1%	-103.6%	-168.5%	-118.1%	-133.4%	-1162.1%	-120.9%
Net Margin	-133.1%	600.9%	81.0%	-177.4%	-153.8%	-128.7%	-3828.3%	-122.0%
Return on Equity	-5.0%-27.6pp	22.7%+18.1pp	4.5%+13.2pp	-8.7%-0.8pp	-7.9%-2.1pp	-5.7%+1.5pp	-7.2%-1.7pp	-5.5%
Return on Assets	-4.3%-24.1pp	19.9%+16.5pp	3.4%+9.8pp	-6.4%-0.4pp	-6.0%-1.5pp	-4.5%+1.1pp	-5.6%-1.6pp	-4.0%
Current Ratio	9.10-3.3x	12.36+8.2x	4.19-0.2x	4.38-0.8x	5.16-1.0x	6.12+0.4x	5.70+1.9x	3.76
Debt-to-Equity	0.160.0x	0.14-0.2x	0.340.0x	0.350.0x	0.310.0x	0.28+0.3x	0.00-0.1x	0.11
FCF Margin	-53.0%	-223.1%	-7.0%	-118.1%	-103.6%	-174.8%	-1959.7%	-136.4%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

ZIMVIE INC ZIMV

$535.7M

Cytek Biosciences, Inc. CTKB

$608.3M

Bioventus Inc. BVS

$945.3M

Orthopedia KIDS

$617.5M

Avanos Medical AVNS

$1.2B

Where STANDARD BIOTOOLS INC Ranks

Frequently Asked Questions

What is STANDARD BIOTOOLS INC's annual revenue?

STANDARD BIOTOOLS INC (LAB) reported $85.3M in total revenue for fiscal year 2025. This represents a -6.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is STANDARD BIOTOOLS INC's revenue growing?

STANDARD BIOTOOLS INC (LAB) revenue declined by 6.2% year-over-year, from $91.0M to $85.3M in fiscal year 2025.

Is STANDARD BIOTOOLS INC profitable?

No, STANDARD BIOTOOLS INC (LAB) reported a net income of -$74.9M in fiscal year 2025, with a net profit margin of -87.8%.

What is STANDARD BIOTOOLS INC's EBITDA?

STANDARD BIOTOOLS INC (LAB) had EBITDA of -$101.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is STANDARD BIOTOOLS INC's gross margin?

STANDARD BIOTOOLS INC (LAB) had a gross margin of 49.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is STANDARD BIOTOOLS INC's net profit margin?

STANDARD BIOTOOLS INC (LAB) had a net profit margin of -87.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is STANDARD BIOTOOLS INC's return on equity (ROE)?

STANDARD BIOTOOLS INC (LAB) has a return on equity of -17.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is STANDARD BIOTOOLS INC's free cash flow?

STANDARD BIOTOOLS INC (LAB) recorded an outflow of $82.6M in free cash flow during fiscal year 2025. This represents a 45.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is STANDARD BIOTOOLS INC's operating cash flow?

STANDARD BIOTOOLS INC (LAB) recorded an outflow of $74.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are STANDARD BIOTOOLS INC's total assets?

STANDARD BIOTOOLS INC (LAB) had $567.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are STANDARD BIOTOOLS INC's capital expenditures?

STANDARD BIOTOOLS INC (LAB) invested $8.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does STANDARD BIOTOOLS INC spend on research and development?

STANDARD BIOTOOLS INC (LAB) invested $26.0M in research and development during fiscal year 2025.

How many shares does STANDARD BIOTOOLS INC have outstanding?

STANDARD BIOTOOLS INC (LAB) had 390M shares outstanding as of fiscal year 2025.

What is STANDARD BIOTOOLS INC's current ratio?

STANDARD BIOTOOLS INC (LAB) had a current ratio of 4.19 as of fiscal year 2025, which is generally considered healthy.

What is STANDARD BIOTOOLS INC's debt-to-equity ratio?

STANDARD BIOTOOLS INC (LAB) had a debt-to-equity ratio of 0.34 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is STANDARD BIOTOOLS INC's return on assets (ROA)?

STANDARD BIOTOOLS INC (LAB) had a return on assets of -13.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does STANDARD BIOTOOLS INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, STANDARD BIOTOOLS INC (LAB) held $213.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $74.3M over that year. Dividing the one by the other, the reported balance equals about 34 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is STANDARD BIOTOOLS INC's Altman Z-Score?

STANDARD BIOTOOLS INC (LAB) has an Altman Z-Score of -1.81, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is STANDARD BIOTOOLS INC's Piotroski F-Score?

STANDARD BIOTOOLS INC (LAB) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are STANDARD BIOTOOLS INC's earnings high quality?

STANDARD BIOTOOLS INC (LAB) reported a net loss of $74.9M while operations used $74.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can STANDARD BIOTOOLS INC cover its interest payments?

STANDARD BIOTOOLS INC (LAB) reported an operating loss of $110.2M against $26K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is STANDARD BIOTOOLS INC?

STANDARD BIOTOOLS INC (LAB) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.